Advertisement
Mr. Raab was chief operating officer of Abbott Laboratories and CEO ofGenentech Inc. For the last 10 years he has been working as chairman and aconsultant to a number of new biotech companies.
Advertisement
"Tom has done a terrific job getting the company to this stage with ourlead product about to enter a robust series of Phase 2 clinical trials inseveral different cancers and a second compound advancing into the clinicearly next year," said Mr. Raab. "We will be searching for a CEO candidate whohas long-term commercial and development experience in oncology as we enter amore advanced stage of pipeline development at BiPar. In the meantime, I willbe involved on a day-to-day basis to keep these promising oncologyopportunities on track."
BiPar is developing multiple compounds designed to inhibit PARP 1(poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulatedin certain tumors. The company plans to begin Phase 2 trials for its leadcandidate BSI-201 later this year in three major cancers.
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stagebiopharmaceutical company developing and commercializing a novel class oftumor-selective drugs designed to meet the significant unmet needs of cancerpatients. The Company's lead product candidate is BSI-201, which is now inearly-stage clinical testing for advanced malignancies. The Company will beevaluating the potential of BSI-201 in multiple cancers and expects to fileinvestigational new drug applications on as many as two additional cancer drugcandidates in early 2008.
SOURCE BiPar Sciences Inc.
